| Huang, Jing |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
NCT06194734: A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer |
|
|
| Recruiting | 3 | 490 | RoW | KC1036, Irinotecan, Docetaxel, S-1, Tegafur-gimeracil-oteracil potassium | Beijing Konruns Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinoma | 12/26 | 12/27 | | |
NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 190 | RoW | HX008, Investigator's Choice Chemotherapy | Taizhou Hanzhong biomedical co. LTD | Metastatic Colorectal Cancer | 01/26 | 10/28 | | |
NCT04886271: Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors |
|
|
| Active, not recruiting | 2 | 210 | RoW | HX009 | Waterstone Hanxbio Pty Ltd | Advanced Solid Tumor | 12/22 | 02/23 | | |
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients |
|
|
| Active, not recruiting | 2 | 170 | US, RoW | OQL011, Vehicle Ointment | OnQuality Pharmaceuticals (USA) LLC | Hand-Foot Skin Reaction (HFSR) | 02/24 | 06/24 | | |
NCT05648006: First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer |
|
|
| Terminated | 2 | 7 | RoW | OH2, Capecitabine, Bevacizumab | Binhui Biopharmaceutical Co., Ltd. | Advanced Colorectal Carcinoma | 04/24 | 04/24 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms |
|
|
| Recruiting | 1 | 94 | RoW | LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus | Taizhou HoudeAoke Biomedical Co., Ltd. | Digestive System Neoplasms | 06/21 | 06/22 | | |
| Recruiting | 1 | 228 | RoW | Recombinant Humanized Monoclonal Antibody MIL93 | Beijing Mabworks Biotech Co., Ltd. | Advanced Malignancies | 08/25 | 08/25 | | |
NCT06205082: A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor |
|
|
| Enrolling by invitation | 1 | 81 | RoW | LIT-00814 | LittDD Medicines Ltd | Advanced Solid Tumor | 10/25 | 06/26 | | |
NCT06143007: A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 42 | RoW | BB3008 tablet, BB3008 | BrodenBio Co., Ltd. | Advanced Solid Tumor | 11/25 | 04/26 | | |
NCT05795829: Ultrasound Ablation for Essential Hypertension（FIM） |
|
|
| Recruiting | N/A | 10 | RoW | disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument | Lepu Medical Technology (Beijing) Co., Ltd. | Uncontrolled Essential Hypertension | 12/23 | 02/24 | | |
| Wu, Renrong |
| No trials found |
